Iscalimab (CFZ533) in patients with sjögren’s disease: Week 24 efficacy and safety results of a randomized, placebo-controlled, phase 2b dose-ranging study - Benjamin, A Fisher; Xavier, Mariette; Athena, S Papas
Arthritis Rheumatol 2023; 75 (suppl 9)